DK1524975T3 - Forbedret, transdermalt tilförselssystem til indgivelse af rotigotin - Google Patents

Forbedret, transdermalt tilförselssystem til indgivelse af rotigotin

Info

Publication number
DK1524975T3
DK1524975T3 DK03766331T DK03766331T DK1524975T3 DK 1524975 T3 DK1524975 T3 DK 1524975T3 DK 03766331 T DK03766331 T DK 03766331T DK 03766331 T DK03766331 T DK 03766331T DK 1524975 T3 DK1524975 T3 DK 1524975T3
Authority
DK
Denmark
Prior art keywords
rotigotine
matrix
tds
delivery system
transdermal delivery
Prior art date
Application number
DK03766331T
Other languages
English (en)
Inventor
Mike Hannay
Dietrich Wilhelm Schacht
Hans-Michael Wolff
Original Assignee
Sanol Arznei Schwarz Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanol Arznei Schwarz Gmbh filed Critical Sanol Arznei Schwarz Gmbh
Application granted granted Critical
Publication of DK1524975T3 publication Critical patent/DK1524975T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK03766331T 2002-07-30 2003-07-28 Forbedret, transdermalt tilförselssystem til indgivelse af rotigotin DK1524975T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02016860A EP1386605A1 (en) 2002-07-30 2002-07-30 Improved transdermal delivery system for the administration of rotigotine

Publications (1)

Publication Number Publication Date
DK1524975T3 true DK1524975T3 (da) 2006-07-31

Family

ID=30011090

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03766331T DK1524975T3 (da) 2002-07-30 2003-07-28 Forbedret, transdermalt tilförselssystem til indgivelse af rotigotin

Country Status (19)

Country Link
EP (2) EP1386605A1 (da)
JP (2) JP4837916B2 (da)
KR (1) KR101016838B1 (da)
CN (2) CN101953819A (da)
AT (1) ATE322263T1 (da)
AU (1) AU2003258539B2 (da)
BR (1) BR0313091A (da)
CA (1) CA2491366A1 (da)
DE (1) DE60304477T2 (da)
DK (1) DK1524975T3 (da)
ES (1) ES2256780T3 (da)
IL (1) IL165918A0 (da)
MX (1) MXPA05000350A (da)
NO (1) NO333297B1 (da)
PL (1) PL217079B1 (da)
PT (1) PT1524975E (da)
SI (1) SI1524975T1 (da)
WO (1) WO2004012730A1 (da)
ZA (1) ZA200500252B (da)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1386605A1 (en) * 2002-07-30 2004-02-04 Schwarz Pharma Ag Improved transdermal delivery system for the administration of rotigotine
EP1386604A1 (en) * 2002-07-30 2004-02-04 Schwarz Pharma Ag Improved transdermal delivery system
DE10361258A1 (de) 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson
DE10361259A1 (de) * 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von Rotigotine in einem Frühstadium von Morbus Parkinson zur Prävention des weiteren Neuronenverlustes
DE102004014841B4 (de) 2004-03-24 2006-07-06 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms
JP2008514376A (ja) * 2004-09-29 2008-05-08 シュウォーツ ファーマ インコーポレイテッド パーキンソン病のための経皮治療システム
US7353034B2 (en) 2005-04-04 2008-04-01 X One, Inc. Location sharing and tracking using mobile phones or other wireless devices
EP2349230A2 (en) * 2008-10-06 2011-08-03 Mylan Technologies, Inc. Amorphous rotigotine transdermal system
DE102008060203A1 (de) 2008-12-07 2010-06-10 Dietrich Wilhelm Schacht Wirkstoffstabilisierende flächenförmige Vorrichtung
EP2201941A1 (de) 2008-12-29 2010-06-30 UCB Pharma GmbH Pflaster-Herstellungstechnologie
CA2767068C (en) * 2009-12-22 2016-09-27 Ucb Pharma Gmbh Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine
AU2011248904B2 (en) 2010-04-30 2014-02-27 Teikoku Seiyaku Co., Ltd. Propynylaminoindan transdermal compositions
JP5906302B2 (ja) 2011-03-24 2016-04-20 テイコク ファーマ ユーエスエー インコーポレーテッド 作用剤層および作用剤変換層を含む経皮組成物
EP2559435A1 (en) 2011-08-19 2013-02-20 UCB Pharma GmbH Rotigotine in the treatment of hemispatial neglect, stroke and deficits following stroke
US9913812B2 (en) 2011-11-09 2018-03-13 Teikoku Pharma Usa, Inc. Methods for the treatment of skin neoplasms
DE102011119043A1 (de) 2011-11-22 2013-05-23 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Transdermales therapeutisches System (TDS) mit Rotigotin
DE102011090178A1 (de) 2011-12-30 2013-07-04 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System mit geringer Neigung zur Spontankristallisation
JP6180520B2 (ja) * 2012-07-05 2017-08-16 エスケー ケミカルス カンパニー リミテッド ロチゴチンを含有した経皮吸収製剤（Ｔｒａｎｓｄｅｒｍａｌｃｏｍｐｏｓｉｔｉｏｎｃｏｍｐｒｉｓｉｎｇｒｏｔｉｇｏｔｉｎｅ）
KR101856515B1 (ko) 2012-11-02 2018-05-10 테이코쿠 팔마 유에스에이, 인코포레이티드 프로피닐아미노인단 경피 조성물
TW201431570A (zh) 2012-11-22 2014-08-16 Ucb Pharma Gmbh 用於經皮投服羅替戈汀（Ｒｏｔｉｇｏｔｉｎｅ）之多天式貼片
JP2016135744A (ja) * 2013-05-08 2016-07-28 株式会社 ケイ・エム トランスダーム 貼付剤
WO2014198422A1 (de) 2013-06-14 2014-12-18 Tesa Labtec Gmbh Transdermales therapiesystem (tts) mit rotigotin
WO2014198423A1 (de) 2013-06-14 2014-12-18 Tesa Labtec Gmbh Dreischichtiges transdermales therapiesystem (tts)
US10046151B2 (en) 2013-07-03 2018-08-14 Lts Lohmann Therapie-Systeme, Ag Transdermal therapeutic system with electronic component
WO2015177212A1 (en) * 2014-05-20 2015-11-26 Lts Lohmann Therapie-Systeme Ag Transdermal delivery system including an interface mediator
JP6895755B2 (ja) * 2014-05-20 2021-06-30 エルテーエス ローマン テラピー−ジステーメ アーゲー 経皮送達システムにおける活性薬剤の放出を調節するための方法
ES2924899T3 (es) * 2014-05-20 2022-10-11 Lts Lohmann Therapie Systeme Ag Sistema de administración transdérmica que contiene rotigotina
KR102364378B1 (ko) * 2014-05-21 2022-02-16 에스케이케미칼 주식회사 안정성을 향상시킨 로티고틴 함유 경피흡수제제
CN104382850B (zh) * 2014-10-17 2017-12-22 烟台大学 一种罗替戈汀微乳及微乳凝胶
WO2019234662A1 (en) * 2018-06-07 2019-12-12 Nal Pharmaceutical Group Limited Transdermal drug delivery system containing rotigotine
EP3854388B1 (de) 2020-01-24 2023-10-04 Luye Pharma Switzerland AG Transdermales therapeutisches system mit dem wirkstoff rotigotin und mindestens einem nicht aminresistenten silikonkleber

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5989586A (en) * 1992-10-05 1999-11-23 Cygnus, Inc. Two-phase matrix for sustained release drug delivery device
AUPN814496A0 (en) * 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
DE19814083C2 (de) * 1998-03-30 2002-02-07 Lohmann Therapie Syst Lts Verfahren zur Herstellung von transdermalen therapeutischen Systemen unter Verwendung von basischen Alkalimetallsalzen zur Umwandlung von Wirkstoffsalzen in die freien Basen
DE19814084B4 (de) * 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
DE19940238A1 (de) * 1999-08-25 2001-03-01 Lohmann Therapie Syst Lts Wirkstoffhaltiges therapeutisches System zur Applikation auf der Haut mit mindestens zwei polymerhaltigen Schichten
ATE246919T1 (de) * 2001-05-08 2003-08-15 Sanol Arznei Schwarz Gmbh Verbessertes transdermales therapeutisches system zur behandlung von morbus parkinson
EP1386604A1 (en) * 2002-07-30 2004-02-04 Schwarz Pharma Ag Improved transdermal delivery system
EP1386605A1 (en) * 2002-07-30 2004-02-04 Schwarz Pharma Ag Improved transdermal delivery system for the administration of rotigotine

Also Published As

Publication number Publication date
JP4837916B2 (ja) 2011-12-14
ES2256780T3 (es) 2006-07-16
PL374814A1 (en) 2005-10-31
PL217079B1 (pl) 2014-06-30
IL165918A0 (en) 2006-01-15
KR20050056942A (ko) 2005-06-16
CN1671375A (zh) 2005-09-21
DE60304477D1 (de) 2006-05-18
CN101953819A (zh) 2011-01-26
EP1524975B1 (en) 2006-04-05
KR101016838B1 (ko) 2011-02-22
ATE322263T1 (de) 2006-04-15
ZA200500252B (en) 2006-01-25
AU2003258539B2 (en) 2008-08-21
EP1524975B9 (en) 2012-02-22
MXPA05000350A (es) 2005-03-31
JP5564469B2 (ja) 2014-07-30
JP2005535687A (ja) 2005-11-24
EP1386605A1 (en) 2004-02-04
NO333297B1 (no) 2013-04-29
WO2004012730A1 (en) 2004-02-12
BR0313091A (pt) 2005-06-21
EP1524975A1 (en) 2005-04-27
NO20050472L (no) 2005-01-27
DE60304477T2 (de) 2006-12-14
PT1524975E (pt) 2006-07-31
CA2491366A1 (en) 2004-02-12
AU2003258539A1 (en) 2004-02-23
SI1524975T1 (sl) 2006-06-30
JP2011219485A (ja) 2011-11-04

Similar Documents

Publication Publication Date Title
NO20050472L (no) Forbedret transdermalt leveringssystem for administrering av rotigotin
HK1083458A1 (en) Improved transdermal delivery system
MXPA04001676A (es) Sistema terapeutico transdermico con fentanilo o sustancias relacionadas.
TW570815B (en) Transdermal therapeutic system (TTS) containing the active substance fentanyl
TW200621319A (en) Transdermal therapeutic system with an adhesive layer, method of siliconizing a backing layer of the system, and use of the backing layer
ATE366567T1 (de) Transdermales therapeutisches system mit hochdispersem siliziumdioxid
WO2001068060A3 (de) Stabilisierte übersättigte transdermale therapeutische matrixsysteme
DK0474647T3 (da) Fremgangsmåde og indretning til frigivelse af lægemidler til huden
ATE396714T1 (de) Transdermales therapeutisches system mit verbessertem langzeittragekomfort
RU2009137122A (ru) Устройство для трансдермального введения бисопролола
DK1143938T3 (da) Transdermalt terapeutisk system med en selvklæbende matrix, der indeholder organiske syreadditionssalte af alkaloider af morphin- eller morphin-type
DK1251853T3 (da) Transdermalt terapeutisk system til indgivelse af zaleplon
ATE214606T1 (de) Transdermales therapeutisches system mit dem wirkstoff scopolaminbase
TW200719902A (en) Solid transdermal therapeutic system with uv absorber
ATE485817T1 (de) Pflaster, enthaltend fentanylum